HOME | NEWS ALERT | HEBREW 
The NurOwn Transplantation Process
A sample of the patient's bone marrow is harvested, and the Mesenchymal Stem Cells (MSCs) are isolated. Read More...
International Innovation
BrainStorm is featured in the May 2013 issue of International Innovation. Read More... Welcome to BrainStorm Cell Therapeutics
BrainStorm (OTC.QB:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
At BrainStorm we believe that NurOwn™, our proprietary, first-of-its-kind technology for the propagation and differentiation of autologous Mesenchymal Stem Cells (MSCs) into NeuroTrophic Factor (NTF)-secreting cells and their transplantation at or near the site of damage, offers the hope of conquering neurodegenerative diseases. Read more...
To see the Scientific Poster presented at the American Academy of Neurology meeting on March 20, 2013 click here.